top of page

News and announcements

PeptiSystems completes a beta-testing project with Bachem evaluating new peptide synthesis instrument technology – PeptiPilot.

Uppsala, Sweden, November 14, 2022

PeptiSystems announces that it has completed beta-testing and evaluation of PeptiSystems, the new generation of peptide synthesis instruments, together with Bachem, a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides. 


The instrument, PeptiPilot, is based on flow-through column technology, which has been used extensively for the solid-phase synthesis of oligonucleotides but has not successfully been applied to peptide synthesis. This technology can be used for process development and large-scale commercial manufacturing of non-GMP and GMP quality peptides. PeptiSystems’ flow-through column technology enables real-time continuous monitoring of the synthesis to increase synthesis control, automation, and productivity while maintaining the same or achieving higher purity and yield compared to current stirred-bed batch reactor technologies. 


Lars Holmberg, PeptiSystems’ CEO comments, “We are excited that Bachem has successfully completed the beta-testing of PeptiPilot. Bachems' expertise and feedback are very valuable to us in the continued development of these instruments and our mission towards greener and more efficient peptide manufacturing.”

About PeptiSystems

PeptiSystems, based in Uppsala, Sweden, develops instruments for process development and manufacturing of peptide and oligonucleotide therapeutics based on flow-through column technology. Utilizing the solid-phase synthesis approach, the instruments are designed to reduce solvent consumption, improve synthesis control, and reduce synthesis time while maintaining equal or achieving higher purity and yield compared to what is obtained with current technologies. This new generation of synthesis instruments provides a higher degree of automation and a greener manufacturing process. 

For more information, please contact Lars Holmberg, CEO at PeptiSystems: or visit our website at

bottom of page